Search Results - "Pilie, P."

Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes by Pilie, P., Werbel, W.A., Riddell IV, J., Shu, X., Schaubel, D., Gregg, K.S.

“…Background Respiratory syncytial virus (RSV) is a common community‐acquired pathogen responsible for a substantial disease burden in adults. We investigated…”
Get full text

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types by McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Lim, B., Ueno, N.T., Litton, J.K., Ferrarotto, R., Chang, J.T., Moulder, S.L., Lin, S.-Y.

“…High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential…”
Get full text

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay by McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Ueno, N.T., Ferrarotto, R., Chang, J.T., Lin, S.-Y.

Get full text

Patient selection biomarker strategies for PARP inhibitor therapy by Pilié, P.G., George, A., Yap, T.A.

Get full text

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al by McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Ueno, N.T., Ferrarotto, R., Chang, J.T., Lin, S.-Y.

Get full text

Abstract No. 139 Cryoablation of Prostate Cancer Metastases: A Single-Center Retrospective Study by Pal, K., Habibollahi, P., Huang, S., Kuban, J., Metwalli, Z., Patel, M., Yevich, S., Tam, A., Gupta, S., Siddiqui, B., Pilie, P., Aparicio, A., Subudhi, S., Sheth, R.

Get full text

Abstract No. 144 Percutaneous Thermal Ablation of Metastatic Prostate Cancer to the Liver: A Single-Center Retrospective Study by Mohanty, S., Pal, K., Paolucci, I., Habibollahi, P., Huang, S., Kuban, J., Metwalli, Z., Patel, M., Yevich, S., Tam, A., Gupta, S., Pilie, P., Aparicio, A., Siddiqui, B., Subudhi, S., Odisio, B., Sheth, R.

Get full text

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer (EXTEND): A Multicenter, Randomized Phase II Trial by Tang, C., Sherry, A.D., Haymaker, C., Bathala, T., Liu, S., Fellman, B., Aparicio, A., Zurita-Saavedra, A., Chun, S.., Reddy, J., Efstathiou, E., Wang, J., Pilie, P., Reuben, A., Kovitz, C., Kumar, R., Chapin, B., Gomez, D.R., Wistuba, I., Corn, P.G.

“…There has been increased utilization of metastasis directed therapy (MDT) for oligometastatic prostate cancer. Despite data demonstrating the benefit of…”
Get full text

DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial: Phase 1/2 Study of the ATR inhibitor (ATRi) berzosertib and PD-L1 inhibitor avelumab in patients (pts) with advanced solid tumors with DDR molecular alterations by Ngoi, N., Pilie, P.G., Piha-Paul, S.A., Dumbrava, E.E., Fu, S., Hong, D.S., Karp, D.D., Naing, A., Pant, S., Rodon Ahnert, J., Subbiah, V., Tsimberidou, A.M., Salguero, C., Brown, C.V., Hoadley, W.E., Johnson, A., Yuan, Y., Westin, S.N., Meric-Bernstam, F., Yap, T.A.

Get full text

Abstract SP084: Replication stress response defects predict responses to ICT in non-hypermutated tumors by McGrail, D, Pilié, P, Zhang, XHF, Rosen, J, Voorwerk, L, Kok, M, Heimberger, A, Peterson, C, Jonasch, E, Lin, S

“…Immune checkpoint blockade (ICT) has provided robust, durable responses to a subset of patients. Many initial ICT trials were focused on highly mutated cancer…”
Get full text